Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
D1.264 - Assessment by general practitioners of a therapeutic patient education guide for allergic patients
D1.262 - Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom
D1.265 - Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan
D1.266 - Investigation of anaphylaxis in mastocytosis mouse models
D1.267 - Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort
D1.268 - The endothelial glycocalyx as a therapeutic target in anaphylaxis
D1.269 - Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells
D1.270 - Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences
D1.271 - Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications
D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom
D1.273 - Anaphylactic Reaction Following Sulphur Hexafluoride Administration
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download